-
Cerus Corporation reports preliminary 2025 revenue of $206.1 million
-
Cerus signs group purchasing pact with Blood Centers of America
-
BTIG Reiterates Neutral Rating on Cerus Corporation (CERS)
-
Cerus (CERS) Tops Q3 EPS by 3c ; Offers Guidance
-
Cerus to host industry workshop on fibrinogen complex at AABB meeting
-
TD Cowen Reiterates Buy Rating on Cerus (CERS)
-
BTIG Reiterates Neutral Rating on Cerus (CERS)
-
Cantor Fitzgerald Reiterates Overweight Rating on Cerus (CERS)
-
Cerus (CERS) Reports In-Line Q2 EPS ; Offers Guidance
-
Cerus receives $7.2 million DoD contract for trauma bleeding study
-
Cerus (CERS) Provides INTERCEPT Red Blood Cell CE Mark Application Update
-
Cantor Fitzgerald Reiterates Overweight Rating on Cerus (CERS)
-
Cerus (CERS) Presents Clinical Data for INTERCEPT Blood System
-
Cerus (CERS) Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device
-
Cerus (CERS) Reports In-Line Q1 EPS, provides guidance
-
Cantor Fitzgerald newsletter says Elutia best, Anteris worst performer
-
Cerus (CERS) PT Maintained at $4 at Cantor Fitzgerald
-
Cerus (CERS) Tops Q4 EPS by 1c, Beats on Revenue
-
Cerus (CERS) Tops Q3 EPS by 1c ; Offers Guidance
-
TD Cowen Reiterates Buy Rating on Cerus (CERS)
-
Cerus (CERS) PT Lowered to $3 at Stifel
-
Cerus (CERS) Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe
-
BTIG Reiterates Neutral Rating on Cerus (CERS)
-
Cerus (CERS) Tops Q2 EPS by 1c, increases product revenue guidance
-
Cerus (CERS) Appoints Dean Gregory to its Board

